KRKazi Mohammad Abidur Rahman

Kazi Mohammad Abidur Rahman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kazi Mohammad Abidur Rahman has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Identifying Gravity-Related Artifacts on Ballistocardiography Signals by Comparing Weightlessness and Normal Gravity Recordings (ARTIFACTS): Protocol for an Observational Study

    by Urs-Vito Albrecht, Annabelle Mielitz, Kazi Mohammad Abidur Rahman, Ulf Kulau

    Background: Modern ballistocardiography (BCG) and seismocardiography (SCG) use acceleration sensors to measure oscillating recoil movements of the body caused by the heartbeat and blood flow, which are transmitted to the body surface. Acceleration artifacts occur through intrinsic sensor roll, pitch, and yaw movements, assessed by the angular velocities of the respective sensor, during measurements that bias the signal interpretation. Objective: This observational study aims to generate hypotheses on the detection and elimination of acceleration artifacts due to the intrinsic rotation of accelerometers and their differentiation from heart-induced sensor accelerations. Methods: Multimodal data from 4 healthy participants (3 male and 1 female) using BCG-SCG and an electrocardiogram will be collected and serve as a basis for signal characterization, model modulation, and location vector derivation under parabolic flight conditions from µg to 1.8g. The data will be obtained during a parabolic flight campaign (3 times 30 parabolas) between September 24 and July 25 (depending on the flight schedule). To detect the described acceleration artifacts, accelerometers and gyroscopes (6-degree-of-freedom sensors) will be used for measuring acceleration and angular velocities attributed to intrinsic sensor rotation. Changes in acceleration and angular velocities will be explored by conducting descriptive data analysis of resting participants sitting upright in varying gravitational states. Results: A multimodal data set will serve as a basis for research into a noninvasive and gentle method of BCG-SCG with the aid of low-noise and synchronous 3D gyroscopes and 3D acceleration sensors. Hypotheses will be generated related to detecting and eliminating acceleration artifacts due to the intrinsic rotation of accelerometers and gyroscopes (6-degree-of-freedom sensors) and their differentiation from heart-induced sensor accelerations. Data will be collected entirely and exclusively during the parabolic flights, taking place between September 2024 and July 2025. Thus, as of June 2024, no data have been collected yet. The data will be analyzed until December 2025. The results are expected to be published by June 2026. Conclusions: The study will contribute to understanding artificial acceleration bias to signal readings. It will be a first approach for a detection and elimination method. Trial Registration: Deutsches Register Klinische Studien DRKS00034402; https://drks.de/search/en/trial/DRKS00034402 International Registered Report Identifier (IRRID): PRR1-10.2196/63306


  • Open Access

    Identifying Gravity-Related Artifacts on Ballistocardiography Signals by Comparing Weightlessness and Normal Gravity Recordings (ARTIFACTS): Protocol for an Observational Study (Preprint)

    by Urs-Vito Albrecht, Annabelle Mielitz, Kazi Mohammad Abidur Rahman, Ulf Kulau

    BACKGROUND Modern ballistocardiography (BCG) and seismocardiography (SCG) use acceleration sensors to measure oscillating recoil movements of the body caused by the heartbeat and blood flow, which are transmitted to the body surface. Acceleration artifacts occur through intrinsic sensor roll, pitch, and yaw movements, assessed by the angular velocities of the respective sensor, during measurements that bias the signal interpretation. OBJECTIVE This observational study aims to generate hypotheses on the detection and elimination of acceleration artifacts due to the intrinsic rotation of accelerometers and their differentiation from heart-induced sensor accelerations. METHODS Multimodal data from 4 healthy participants (3 male and 1 female) using BCG-SCG and an electrocardiogram will be collected and serve as a basis for signal characterization, model modulation, and location vector derivation under parabolic flight conditions from µg to 1.8g. The data will be obtained during a parabolic flight campaign (3 times 30 parabolas) between September 24 and July 25 (depending on the flight schedule). To detect the described acceleration artifacts, accelerometers and gyroscopes (6-degree-of-freedom sensors) will be used for measuring acceleration and angular velocities attributed to intrinsic sensor rotation. Changes in acceleration and angular velocities will be explored by conducting descriptive data analysis of resting participants sitting upright in varying gravitational states. RESULTS A multimodal data set will serve as a basis for research into a noninvasive and gentle method of BCG-SCG with the aid of low-noise and synchronous 3D gyroscopes and 3D acceleration sensors. Hypotheses will be generated related to detecting and eliminating acceleration artifacts due to the intrinsic rotation of accelerometers and gyroscopes (6-degree-of-freedom sensors) and their differentiation from heart-induced sensor accelerations. Data will be collected entirely and exclusively during the parabolic flights, taking place between September 2024 and July 2025. Thus, as of June 2024, no data have been collected yet. The data will be analyzed until December 2025. The results are expected to be published by June 2026. CONCLUSIONS The study will contribute to understanding artificial acceleration bias to signal readings. It will be a first approach for a detection and elimination method. CLINICALTRIAL Deutsches Register Klinische Studien DRKS00034402; https://drks.de/search/en/trial/DRKS00034402 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/63306

  • Open Access

    Cholesterol binds the amphipathic helix of IFITM3 and regulates antiviral activity

    by Kazi Rahman, Siddhartha A.K. Datta, Andrew H. Beaven, Abigail A. Jolley, Alexander J. Sodt, Alex A. Compton

    The interferon-induced transmembrane (IFITM) proteins broadly inhibit the entry of diverse pathogenic viruses, including Influenza A virus (IAV), Zika virus, HIV-1, and SARS coronaviruses by inhibiting virus-cell membrane fusion. IFITM3 was previously shown to disrupt cholesterol trafficking, but the functional relationship between IFITM3 and cholesterol remains unclear. We previously showed that inhibition of IAV entry by IFITM3 is associated with its ability to promote cellular membrane rigidity, and these activities are functionally linked by a shared requirement for the amphipathic helix (AH) found in the intramembrane domain (IMD) of IFITM3. Furthermore, it has been shown that the AH of IFITM3 alters lipid membranes in vitro in a cholesterol-dependent manner. Therefore, we aimed to elucidate the relationship between IFITM3 and cholesterol in more detail. Using a fluorescence-based in vitro binding assay, we found that a peptide derived from the AH of IFITM3 directly interacted with the cholesterol analog, NBD-cholesterol, while other regions of the IFITM3 IMD did not, and native cholesterol competed with this interaction. In addition, recombinant full-length IFITM3 protein also exhibited NBD-cholesterol binding activity. Importantly, previously characterized mutations within the AH of IFITM3 that strongly inhibit antiviral function (F63Q and F67Q) disrupted AH structure in solution, inhibited cholesterol binding in vitro , and restricted bilayer insertion in silico . Our data suggest that direct interactions with cholesterol may contribute to the inhibition of membrane fusion pore formation by IFITM3. These findings may facilitate the design of therapeutic peptides for use in broad-spectrum antiviral therapy.